Kinetics of endocan in patients undergoing cardiac surgery with and without cardiopulmonary bypass

Poinsot, Pierre-Alain; Barrucand, Benoit; Ecarnot, Fiona; Lassalle, Philippe; Besch, Guillaume; Chocron, Sidney; Perrotti, Andréa

doi:10.1016/j.cyto.2018.03.040

Cited by 2 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that decrease in endocan levels was associated with the reduction of the amount of stress-induced ischemia. Our study findings agree with those studies which evaluated the impact of coronary artery bypass grafting on the dynamics of endocan levels and showed a trend of decreasing after cardiac surgery (64)(65)(66).…”

Section: Figuresupporting

confidence: 92%

The association of catestatin and endocan with the effects of cardiac shock wave therapy: Biomarker sub-study of the randomized, sham procedure-controlled trial

Burneikaitė

Shkolnik²,

Puronaitė³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

IntroductionCardiac shock-wave therapy (CSWT) is a non-invasive regenerative treatment method based on low-frequency ultrasound waves, which stimulate angiogenesis. Current data about the effects of revascularization procedures on angiogenesis biomarkers is limited. Recently, an association of catestatin and endocan with coronary collateral development was shown in several trials. In this study, we aimed to evaluate the impact of CSWT on the dynamics of catestatin and endocan levels and to assess their correlation with parameters of myocardial perfusion and function.MethodsProspective, randomized, triple-blind, sham procedure-controlled study enrolled 72 adult subjects who complied with defined inclusion criteria (NCT02339454). We measured biomarkers in 48 patients with stable angina (24 patients of CSWT group, 24 patients of sham-procedure group). Additionally, patients were divided into responders and non-responders according to improvement in myocardial perfusion and/or contractility assessed by myocardial scintigraphy and dobutamine echocardiography (30 and 13 patients, respectively). The blood samples were collected at baseline, after the last treatment procedure (9th treatment week) and at 6-month follow-up to evaluate biomarkers concentration and stored at –80° until analysis. Serum catestatin and endocan levels were determined by commercially available ELISA kits.ResultsSerum catestatin concentration significantly increased in all patients. While endocan levels significantly decreased in the responders sub-group. The increase in catestatin levels at 9th week and 6 months was positively associated with improvement in summed difference score (rho = 0.356, p = 0.028) and wall motion score, WMS (rho = 0.397, p = 0.009) at 6 months in the whole study population. Meanwhile, the decrease in endocan levels over 6 months was positively correlated with improvement in WMS at 3- and 6- months (r = 0.378, p = 0.015 and r = 0.311, p = 0.045, respectively). ROC analysis revealed that a change at 6 months in catestatin and endocan levels significantly predicted improvement in myocardial perfusion and contractile function with 68.9% sensitivity and 75.0% specificity (p = 0.039) and 51.7% sensitivity, and 91.7% specificity (p = 0.017), respectively. Baseline endocan concentration and its change at 6 months predicted response to CSWT with 68.8% sensitivity and 83.3% specificity (p = 0.039) and 81.3% sensitivity and 100% specificity (p < 0.0001), respectively.ConclusionThis study demonstrates the association of increase in catestatin and decrease in endocan levels with the improvement of myocardial perfusion and contractile function. The potential predictive value of catestatin and endocan dynamics for the response to regenerative therapy is shown.

show abstract

Section: Figuresupporting

confidence: 92%

The association of catestatin and endocan with the effects of cardiac shock wave therapy: Biomarker sub-study of the randomized, sham procedure-controlled trial

Burneikaitė

Shkolnik²,

Puronaitė³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…A total of 330 patients undergoing cardiac surgery with and without the use of cardiopulmonary bypass (CPB) have been investigated for blood endocan. All showed increased endocan levels peaking at 6–24 h post surgery, which then slowly declined yet were not returned to baseline concentrations at day 5 [ 37 – 40 ]. The endocan level in cardiac surgery with CPB peaked earlier at 6 h and was higher than that in patients undergoing off-pump surgery [ 40 , 41 ].…”

Section: Main Textmentioning

confidence: 99%

“…All showed increased endocan levels peaking at 6–24 h post surgery, which then slowly declined yet were not returned to baseline concentrations at day 5 [ 37 – 40 ]. The endocan level in cardiac surgery with CPB peaked earlier at 6 h and was higher than that in patients undergoing off-pump surgery [ 40 , 41 ]. No correlation was found between endocan levels at 6 h post surgery and the duration of CPB [ 40 ].…”

Section: Main Textmentioning

confidence: 99%

“…The endocan level in cardiac surgery with CPB peaked earlier at 6 h and was higher than that in patients undergoing off-pump surgery [ 40 , 41 ]. No correlation was found between endocan levels at 6 h post surgery and the duration of CPB [ 40 ]. Higher perioperative concentrations of endocan were observed in patients with the longest duration of norepinephrine support ( p = 0.007) [ 38 ].…”

Section: Main Textmentioning

confidence: 99%

See 1 more Smart Citation

Endocan, sepsis, pneumonia, and acute respiratory distress syndrome

et al. 2018

Self Cite

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) and hospital-acquired pneumonia (HAP) are major problems of public health in intensive care units (ICUs), occurring in 15% of critically ill patients. Among the factors explaining ARDS development, sepsis is known as a frequent cause. Sepsis, ARDS, and HAP increase morbidity, mortality, length of stay in the ICU, and the overall costs of healthcare. The major challenge remains to identify accurately among critically ill patients those at risk of poor outcomes who could benefit from novel therapies. Endocan is released by the pulmonary endothelium in response to local or systemic injury. It inhibits mainly leukocyte diapedesis rather than leukocyte rolling or adhesion to the endothelial cells both in vitro and in vivo. Endocan was evaluated in 25 clinical reports, including 2454 critically ill patients and 452 healthy controls. The diagnostic value of endocan for sepsis or sepsis severity was equal to procalcitonin but its prognostic value was better. A predictive value for postoperative pneumonia was evidenced in two studies, and a predictive value for ARDS in four studies from three independent centers. This review presents an overview of the structure, expression, and functions of endocan. We also hereby summarize the potential applications of endocan in the prediction and prognosis of ARDS and HAP, as well as in the prognosis of sepsis.

show abstract

Kinetics of endocan in patients undergoing cardiac surgery with and without cardiopulmonary bypass

Cited by 2 publications

References 23 publications

The association of catestatin and endocan with the effects of cardiac shock wave therapy: Biomarker sub-study of the randomized, sham procedure-controlled trial

The association of catestatin and endocan with the effects of cardiac shock wave therapy: Biomarker sub-study of the randomized, sham procedure-controlled trial

Endocan, sepsis, pneumonia, and acute respiratory distress syndrome

Contact Info

Product

Resources

About